Literature DB >> 17439630

Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations.

M Coppens1, N Folkeringa, M J Teune, K Hamulyák, J van der Meer, M H Prins, H R Büller, S Middeldorp.   

Abstract

BACKGROUND: The factor V Leiden (FVL) and prothrombin 20210A (PTm) mutations are associated with single late pregnancy loss and recurrent early pregnancy loss. The prognosis after an initial loss in women with thrombophilia is uncertain.
OBJECTIVE: To assess the pregnancy outcome of the second pregnancy after a first loss in women with and without either FVL or PTm mutations.
METHODS: We selected women with a first pregnancy loss out of two family cohorts of first degree relatives of probands with FVL or PTm mutations and a history of documented venous thromboembolism or premature atherosclerosis.
RESULTS: Ninety-three women had had a first pregnancy loss and became pregnant a second time. Their risk of loss of the subsequent pregnancy was higher than in 825 women with a successful first pregnancy [25 vs. 12%, relative risk (RR) 2.0, 95% CI 1.4-3.0]. The live birth rate of the second pregnancy after an early first loss (<or= 12 weeks of gestation) was 77% (95% CI 62-87) for carriers and 76% (95% CI 57-89) for non-carriers (RR 1.0, 95% CI 0.8-1.3). After a late first loss (> 12 weeks), the live birth rates were 68% (95% CI 46-85) and 80% (95% CI 49-94) for carriers and non-carriers, respectively (RR 0.9, 95% CI 0.5-1.3).
CONCLUSIONS: Women with a first pregnancy loss have a 2-fold increased risk of loss of the subsequent pregnancy, regardless of their carrier status. More importantly, the outcome of the second pregnancy is rather favorable in absolute terms, even for those with thrombophilia and a late loss, which raises concern regarding the risks and presumed benefits of anticoagulant therapy in these women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439630     DOI: 10.1111/j.1538-7836.2007.02586.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  3 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Prothrombin gene G20210A mutation and obstetric complications.

Authors:  Robert M Silver; Yuan Zhao; Catherine Y Spong; Baha Sibai; George Wendel; Katharine Wenstrom; Philip Samuels; Steve N Caritis; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner
Journal:  Obstet Gynecol       Date:  2010-01       Impact factor: 7.623

Review 3.  The role of thrombophilia in pregnancy.

Authors:  Elisabeth M Battinelli; Ariela Marshall; Jean M Connors
Journal:  Thrombosis       Date:  2013-12-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.